The news today concerning RapiMeds and China answers the question asked a few days ago, "is RapiMeds put on the back burner?" Obviously not. Mr. Schneiderman is running his business, maximizing every opportunity, and making the right decisions to grow SCRC shareholder value. Compounding pharmacy is without a doubt leading the way in generating revenues right now, the potential here is untapped. But the RapiMeds PR today for me solidifies SCRC is a diversified company which I believe is an attractive feature to new investors. Revenues increasing on a monthly basis, diversified lines of business, and great leadership. What else does one have to know to make a decision to invest in SCRC? The future is incredible for this little gem. GO SCRC!!!